Supernus Pharmaceuticals

Supernus Pharmaceuticals

Yahoo Finance • 7 days ago

Updated Effective Date: Huron Consulting Group Set to Join S&P SmallCap 600

NEW YORK, Oct. 28, 2026 /PRNewswire/ -- Huron Consulting Group Inc. (NASD: HURN) will replace Supernus Pharmaceuticals Inc. (NASD: SUPN) in the S&P SmallCap 600 before the opening of trading on Tuesday, November 3, instead of Monday, Novem... Full story

Yahoo Finance • 12 days ago

Arrowhead Pharmaceuticals And 2 Biotech Stocks To Own

Biotech stocks live and die on access to capital, so the Federal Reserve's signal that interest rates may pause for now gives this high risk corner of the market some breathing room. Cheaper money can make it easier to fund drug pipelines... Full story

Yahoo Finance • 13 days ago

MSG Rangers and Huron Consulting Group to join S&P SmallCap 600

[Markets Open Thursday Morning After Dow Sheds Over 600 Points] Michael M. Santiago/Getty Images News * MSG Rangers (MSGR) will join [https://seekingalpha.com/pr/20697625-msg-rangers-and-huron-consulting-group-set-to-join-s-and-p-smallc... Full story

Yahoo Finance • 13 days ago

Huron Consulting stock rises on S&P SmallCap 600 addition

Investing.com -- Huron Consulting Group Inc (NASDAQ:HURN) shares rose 2.9% in after-hours trading Thursday following S&P Dow Jones Indices' announcement that the company will join the S&P SmallCap 600 index. Still guessing which stocks wi... Full story

Yahoo Finance • 13 days ago

MSG Rangers and Huron Consulting Group Set to Join S&P SmallCap 600

NEW YORK, Oct. 22, 2026 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P SmallCap 600: MSG Rangers Inc. (NYSE: MSGR) will be added to the S&P SmallCap 600 effective prior to the opening of trading on Tuesda... Full story

Yahoo Finance • 26 days ago

1 Healthcare Stock Worth Your Attention and 2 We Turn Down

1 Healthcare Stock Worth Your Attention and 2 We Turn Down From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not only realized strong fin... Full story

Yahoo Finance • last month

3 Reasons SUPN is Risky and 1 Stock to Buy Instead

3 Reasons SUPN is Risky and 1 Stock to Buy Instead Over the last six months, Supernus Pharmaceuticals's shares have sunk to $41.99, producing a disappointing 14.7% loss - a stark contrast to the S&P 500's 16.4% gain. This may have investo... Full story

Yahoo Finance • 2 months ago

3 Cash-Heavy Stocks Walking a Fine Line

3 Cash-Heavy Stocks Walking a Fine Line A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declin... Full story

Yahoo Finance • 2 months ago

Q2 Rundown: Pfizer (NYSE:PFE) Vs Other Branded Pharmaceuticals Stocks

Q2 Rundown: Pfizer (NYSE:PFE) Vs Other Branded Pharmaceuticals Stocks Let's dig into the relative performance of Pfizer (NYSE:PFE) and its peers as we unravel the now-completed Q2 branded pharmaceuticals earnings season. Looking ahead, t... Full story

Yahoo Finance • 3 months ago

Reflecting On Branded Pharmaceuticals Stocks’ Q2 Earnings: Corcept (NASDAQ:CORT)

Reflecting On Branded Pharmaceuticals Stocks' Q2 Earnings: Corcept (NASDAQ:CORT) Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let's have a look at Corcept (NASDAQ:CORT) and its... Full story

Yahoo Finance • 3 months ago

1 Healthcare Stock with Exciting Potential and 2 We Ignore

1 Healthcare Stock with Exciting Potential and 2 We Ignore Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their... Full story

Yahoo Finance • 3 months ago

Supernus and Indivior merge to create scaled, CNS-focused entity

Supernus Pharmaceuticals and Indivior Pharmaceuticals are joining forces to create a diversified and scaled biopharmaceutical company focused on the central nervous system (CNS). Through this all-stock merger, which is expected to generat... Full story

Yahoo Finance • 3 months ago

Stocks Settle Sharply Higher as Middle East Tensions Ease

The S&P 500 Index ($SPX) (SPY) on Monday closed up +1.48%, the Dow Jones Industrial Average ($DOWI) (DIA) closed up +1.32%, and the Nasdaq 100 Index ($IUXX) (QQQ) closed up +1.78%.  September E-mini S&P futures (ESU26) rose +1.49%, and Sep... Full story

Yahoo Finance • 3 months ago

Halper Sadeh LLC is Investigating Whether SUPN, ITGR, BOW are Obtaining Fair Deals for their Shareholders

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers. Shareholders are encouraged to contact the firm... Full story

Yahoo Finance • 3 months ago

Stocks Rally on Easing Geopolitical Risks and US Economic Strength

The S&P 500 Index ($SPX) (SPY) today is up +1.18%, the Dow Jones Industrial Average ($DOWI) (DIA) is up +1.081%, and the Nasdaq 100 Index ($IUXX) (QQQ) is up +1.40%.  September E-mini S&P futures (ESU26) are up +1.11%, and September E-mini... Full story

Yahoo Finance • 3 months ago

Supernus jumps premarket on merger deal; GameStop drops

Investing.com - U.S. stock index futures advanced on Monday after President Donald Trump said negotiations with Iran were set to begin this week, easing geopolitical concerns that had rattled markets in recent weeks, while technology stock... Full story

Yahoo Finance • 3 months ago

Supernus Pharmaceuticals to Announce Second Quarter 2026 Financial Results and Host Conference Call on August 4, 2026

ROCKVILLE, Md., July 22, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, t... Full story

Yahoo Finance • 4 months ago

1 Growth Stock to Stash and 2 We Turn Down

1 Growth Stock to Stash and 2 We Turn Down Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived through the 2020 to 2022 COVID cycle. Lu... Full story

Yahoo Finance • 4 months ago

Branded Pharmaceuticals Stocks Q1 Teardown: Zoetis (NYSE:ZTS) Vs The Rest

Branded Pharmaceuticals Stocks Q1 Teardown: Zoetis (NYSE:ZTS) Vs The Rest Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let's have a look at Zoetis (NYSE:ZTS) and its peers. Lo... Full story

Yahoo Finance • 5 months ago

3 Reasons to Avoid SUPN and 1 Stock to Buy Instead

3 Reasons to Avoid SUPN and 1 Stock to Buy Instead Over the last six months, Supernus Pharmaceuticals's shares have sunk to $43.79, producing a disappointing 9.4% loss - a stark contrast to the S&P 500's 9.3% gain. This might have investo... Full story